Skip to content

Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation

Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation: a Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06959056
Acronym
CRyoLTRiX
Enrollment
40
Registered
2025-05-06
Start date
2026-01-04
Completion date
2027-12-01
Last updated
2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplant; Pain

Keywords

cryo nerve block, lung transplantation, cryoanalgesia

Brief summary

The goal of this pilot trial is to learn whether the use of cryo nerve block and its effect on sensation in the chest alters recovery after bilateral lung transplantation, and to which extent these parameters are influenced. As this study is setup as a pilot study, the main questions it aims to determine the potential impacted parameters as well as their effect sizes, of cryo-analgesia on both short and long term outcomes following bilateral lung transplantation in COPD patients in a European high volume lung transplant centre. The efficacy parameters under evaluation will be: * is the highest pain score affected by the use of cryo nerve block? * Is there an effect on the lung function ? * Does cryo nerve block cause specific complications? * are patients treated with cryo nerve block still needing the same amount of morphine as a pain killer? * is the length of stay in intensive care influenced by the use of cryo nerve block? * and is the qualiy of life influenced by the use of cryo nerve block? Participants will: * undergo cryo nerve block or receive routine pain treatment after bilateral lung transplantation * be followed up during the first week after the operation, and every month to determine their pain * be asked to perform a lung function test and complete quality of life questionnaires 1, 2, 3, 6 months and 1 year after transplantation

Interventions

DEVICEcryo nerve block at T3-T8 intercostal nerves bilaterally

In order to obtain better analgesia at the level of the chest wall, where the chest is bilaterally opened for lung extraction and donor lung implantation, intraoperative cryo-ablation will be applied to the intercostal nerves at the bilateral intercostal spaces 3-8, 3cm lateral to the sympathetic chain, under direct visualization during surgery, as such covering 2 intercostal levels above as well as below the normal access of ICR 4 or 5. By providing analgesia to level 8, we will also cover the area of chest drains, which also tend to cause pain in the postoperative course, especially when patients start mobilizing at the ward. Each nerve bundle will be cooled to a temperature between -65 and -72 °C during 120 seconds by means of the CyroSphere v2 probe (AtriCure Inc; Mason, OH, USA) connected to the provided instrument tower (AtriCure CryoICE box) including a processor device measuring and regulating the N2O flow through the probe.

Sponsors

University Hospital, Gasthuisberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. At least 18 years of age at the time of signing the Informed Consent Form (ICF) 3. Bilateral lung transplantation at UZ Leuven 4. Indication for transplantation: End stage chronic obstructive pulmonary disease (COPD) 5. Storage of lungs on classic ice, cooled system (LUNGguard® (Paragonix) or X°Port Lung Transport Device (Traferox Technologies Inc.) ) are all permitted 6. Patients that have undergone lung volume reduction or talcage are not a contraindication for participation in the study.

Exclusion criteria

1. Unilateral lung transplantation 2. Lobar transplantation 3. Donor lung reconditioning using ex-vivo lung perfusion (EVLP) 4. Combined organ transplantation 5. Chronic opioid use pre-operatively 6. Participation in an interventional Trial with an investigational medicinal product (IMP) or device (IMD) that could potentially influence the post-operative outcomes of this study

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue pain Scale valuePostoperative days 0 to 7, 14, and 21 and every month postoperative until 1 year postoperativeThe highest pain score throughout the day in a participant, expressed on a Visual Analogue Scale instrument for assessing pain will be recorded. Patients will be asked specifically about thoracic/chest pain and asked to rate this pain on a Likert pain scale of 0-10, 0 being no pain and 10 being the worst pain they can imagine.
Lung function1, 2, 3, 6 and 12 months postoperativeLung function evaluated by spirometry, recorded as Forced Expiratory Value at one second and Functional Vital Capacity expressed in liters and percentage of the expected.
opioid consumptionpostoperative days 1-7, and every monthly contact until 1 year postoperativeuse of iv or oral morphin derivatives including tramadol, as well as transdermal delivery forms, expressed in oral morphine milligram equivalents (OMME)
Length of stay (LOS) at ICUfrom transplantation until actual discharge of the intensive care unit, between 2 days and 6 months postoperativelength of stay at the intensive care unit, expressed in days
Total hospital length of stay (HLOS)from treatment until last day in the hospital of the index admission, between 2 days and 6 months postoperativetotal length of hospital stay, expressed in days
Evaluation of Quality of life - SF12single time points at 1, 2, 3, 6 months and 1 year postoperativeEvaluation of quality of life by completion of standardized Quality of Life questionnaire (Short Form -12 (SF12)); 5 point likert scale; higher score equals better quality of life
Evaluation of Quality of life - EQ5D5Lsingle time points at 1, 2, 3, 6 months and 1 year postoperativeEvaluation of quality of life by completion of standardized Quality of Life questionnaire (Evaluation of Quality of Life in 5 domains at 5 levels (EQ5D5L)); minimum score 5, maximum score 25; lower score equals better quality of life
Evaluation of Quality of life - Brief Pain Inventorysingle time points at 1, 2, 3, 6 months and 1 year postoperativeEvaluation of quality of life by completion of standardized Quality of Life questionnaire (Brief Pain Inventory); lower score equals better quality of life
Evaluation of Neuropathic Painsingle time points at 1, 2, 3, 6 months and 1 year postoperativeEvaluation of pain characteristics in order to probe for neuropathic pain levels by means of the Neuropathic Pain Assessment questionnaire; 5 point likert scale, higher score is worse

Countries

Belgium

Contacts

CONTACTHans Van Veer, MD
hans.vanveer@uzleuven.be+3216346822
CONTACTCeline Rihon, RN
celine.rihon@uzleuven.be+3216345857
PRINCIPAL_INVESTIGATORHans Van Veer, MD

Universitaire Ziekenhuizen KU Leuven

STUDY_CHAIRLaurens Ceulemans, MD, PhD

Universitaire Ziekenhuizen KU Leuven

STUDY_CHAIRYanina Jansen, MD, PhD

Universitaire Ziekenhuizen KU Leuven

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026